Gemfibrozil - CAS 25812-30-0

Gemfibrozil (CI-719) interacts with peroxisome proliferator-activated receptors (PPARalpha) resulting in PPARalpha-mediated stimulation of fatty acid oxidation and an increase in lipoprotein lipase (LPL) synthesis. Gemfibrozil is a fibric acid derivative with hypolipidemic effects. This enhances triglyceride-rich lipoprotein clearance and reduces the expression of apolipoprotein C-III (apoC-III) . The reduction in hepatic production of apoC-III result in the subsequent reduction of serum levels of very-low-density-lipoprotein cholesterol (VLDL-C) . In addition, gemfibrozil-mediated PPARalpha stimulation of apoA-I and apoA-II expression results in an increase in high-density lipoprotein cholesterol (HDL-C) .

PPAR, Cytochromes P450, Adrenergic Receptor

GPCR/G Protein, Metabolism, DNA Damage/DNA Repair, Neuroscience

25782

0.999

C15H22O3

250.33

CC1=CC(OCCCC(C)(C)C(O)=O)=C(C)C=C1

-20°C

Ice Packs

Small Compound